Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chattem ephedra

This article was originally published in The Tan Sheet

Executive Summary

Roughly $2 mil. to $2.5 mil. in ephedra-containing Dexatrim remained on retail shelves as of March, although all such products "should be off shelves by May," Chattem tells investors April 3 at Banc of America Securities Consumer Conference. Chattanooga, Tenn.-based firm took $750,000 hit in Q1 to replace product with new formulation, execs add. Despite charge, first quarter revenue reached $58.4 mil., a 20.7% increase over year-ago period, attributable in part to growing Selsun Blue sales (1"The Tan Sheet" March 24, 2003, In Brief)...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095309

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel